Analyst firms · Deutsche Bank · ACAD
Deutsche Bank ACAD price target and rating history
ACADIA Pharmaceuticals Inc. (ACAD) · Health Care
Deutsche Bank rates ACADIA Pharmaceuticals Inc. (ACAD) Buy with a $35 price target, as of its latest action on May 21, 2025. It has published 4 rating actions on ACAD since December 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
- Current rating
- Buy
- Price target
- $35
- Median target, all firms
- $31
- Actions on ACAD
- 4
Deutsche Bank price target on ACAD
Every Deutsche Bank rating on ACAD
- May 21, 2025
- Feb 11, 2025
- Dec 14, 2023
- Dec 12, 2023
How other firms rate ACAD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $23 | Oct 13, 2026 |
| BofA Securities | Buy | $29 | Mar 25, 2026 |
| Wolfe Research | Outperform | $33 | Feb 24, 2026 |
| Mizuho | Outperform | $35 | Feb 23, 2026 |
Questions about Deutsche Bank and ACAD
- What is Deutsche Bank's price target for ACAD?
- Deutsche Bank's latest stated price target for ACADIA Pharmaceuticals Inc. (ACAD) is $35, from its action on May 21, 2025.
- What is Deutsche Bank's rating on ACAD?
- Deutsche Bank rates ACAD Buy, a bullish rating, as of May 21, 2025.
- When did Deutsche Bank last change its view on ACAD?
- On May 21, 2025, Deutsche Bank upgrades to Buy from Hold, price target $35.
- How does Deutsche Bank's ACAD target compare with other analysts?
- Across 4 firms with a ACAD price target in the last 12 months, the median target is $31.
More ACAD rating histories
All Deutsche Bank ratingsACAD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.